Trials / Completed
CompletedNCT04908761
Quadratus Lumborum Block After Living Donor Kidney Transplantation
Quadratus Lumborum Block for Analgesia After Living Donor Kidney Transplantation: A Randomized Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the postoperative analgesic effect of quadratus lumborum block in patient undergoing a living donor kidney transplant under general anesthesia.
Detailed description
The purpose of this study was to investigate whether postoperative pain is significantly reduced when TQL block was additionally performed after surgery in patients undergoing living-donor kidney transplantation. Therefore, investigator hypothesized that the analgesic consumption for postoperative 24 hours will decrease in TQL group compared to the control group. For secondary outcomes, the pain score at rest/ movement up to 48 hours after surgery, the time until the first pain reliever is requested, whether and how often rescue analgesics are administered for 48 hours, the incidence and severity of nausea and vomiting during the 48 hours after surgery, patient's satisfaction with post-pain control and the number of hospital stays were investigated. Overall, the aim of this study is to evaluate the postoperative analgesic effect of quadratus lumborum block in patients undergoing a living donor kidney transplantation under general anesthesia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Transmuscular quadratus lumborum block | Patients assigned to the TQL block group receive the TQL block in a supine position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used. |
| PROCEDURE | Placebo | For patients assigned to the control group, 30cc of 0.9% normal saline is used for TQL block. |
Timeline
- Start date
- 2021-06-03
- Primary completion
- 2022-05-18
- Completion
- 2022-05-28
- First posted
- 2021-06-01
- Last updated
- 2022-12-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04908761. Inclusion in this directory is not an endorsement.